Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lymphoma, Extranodal NK-T-Cell × Melphalan × Clear all

Phase

Status

Terminated 2 Completed 2 Withdrawn 1 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 22 Lymphoma 16 Neoplasms, Plasma Cell 12 Lymphoma, Non-Hodgkin 11 Lymphoma, Large B-Cell, Diffuse 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neuroblastoma 6 Lymphoma, Mantle-Cell 6 Hodgkin Disease 6 Myelodysplastic Syndromes 5 Lymphoma, Large-Cell, Immunoblastic 5 Leukemia 5 Burkitt Lymphoma 5 Lymphoma, Follicular 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Recurrence 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, Myeloid, Acute 3 Sarcoma 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroectodermal Tumors, Primitive 2 Medulloblastoma 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Biphenotypic, Acute 2 Dendritic Cell Sarcoma, Interdigitating 2 Brain Neoplasms 2

Interventions

pegaspargase 13 Dexamethasone 10 Gemcitabine 8 Etoposide 8 spartalizumab 5 Oxaliplatin 4 sintilimab 3 Methotrexate 3 Asparaginase 3 tislelizumab 2 camrelizumab 2 Radiotherapy 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Cyclophosphamide 2 Busulfan 2 Azacitidine 2 tofacitinib 1 pembrolizumab 1 fludarabine phosphate 1 apatinib 1 Thalidomide 1 Sensitivity and Specificity 1 Psychiatric Rehabilitation 1 Pharmacogenomic Testing 1 PC61 monoclonal antibody 1 Mycophenolic Acid 1 Melphalan 1 Ketamine 1 Ifosfamide 1 Gelox 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02544425 2020-10-22

VIDL+ASCT

Samsung Medical Center

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡